Información del artículo
El grupo farmacológico de las equinocandinas estará enriquecido por la próxima incorporación de nuevos miembros. El primero en comercializarse será anidulafungina, fármaco que presenta algunas características farmacocinéticas que lo distinguen con claridad del único de los representantes de esta familia de antifúngicos que existía hasta el momento: caspofungina. Concretamente, este nuevo fármaco presenta un volumen de distribución mayor, una semivida de eliminación más elevada y, además, un sistema de eliminación, degradación espontánea, que evita su implicación en interacciones con otros fármacos y hace posible su uso sin ajuste de la dosis en pacientes con insuficiencia renal o hepática. Éstas son las mayores diferencias farmacológicas con caspofungina, ya que este último requiere ajuste de la dosis en pacientes con insuficiencia hepática y en los tratados con inductores de la actividad de las isoenzimas del CYP450 y en los pacientes obesos. Además, se recomienda monitorizar las concentraciones plasmáticas de los pacientes que precisan tratamiento con caspofungina y reciban al mismo tiempo ciclosporina A o tacrolimus. De acuerdo con la experiencia clínica acumulada puede afirmarse que hay pocas diferencias en el perfil de tolerabilidad entre ambos fármacos que, en cualquier caso, resulta excelente.
Palabras clave:
Equinocandinas
Farmacocinética
Farmacodinamia
Interacciones
New drugs will soon be incorporated into the echinocandin class of antifungals. The first to be released on to the market will be anidulafungin. The pharmacokinetic characteristics of this drug clearly distinguish it from the only representative of this family of antifungal agents available to date: caspofungin. Specifically, this new drug has a greater volume of distribution, a higher elimination half-life and, moreover, an elimination system - spontaneous degradation -, thus avoiding interactions with other drugs and allowing its use without dosage adjustments in patients with renal or liver impairment. These are the main pharmacological differences between anidulafungin and caspofungin, since the latter requires dosage adjustments in patients with hepatic insufficiency, in patients under treatment with inducers of cytochrome P450 activity and in obese patients. Moreover, plasma concentration monitoring is recommended in patients requiring caspofungin who are also under treatment with cyclosporin A or tacrolimus. Clinical experience suggests that there are few differences in the tolerability profiles of the two drugs, both of which are excellent.
Key words:
Equinocandins
Pharmacokinetic
Pharmacodynamic
Drug interactions
El Texto completo está disponible en PDF
Bibliografía
[1.]
A.H. Groll, D. Mickiene, R. Petraitiene, V. Petraitis, C.A. Lyman, J.S. Bacher, et al.
Pharmacokinetic and pharmacodynamic modeling of anidulafungin (LY303366): reappraisal of its efficacy in neutropenic animal models of opportunistic mycoses using optimal plasma sampling.
Antimicrob Agents Chemother, 45 (2001), pp. 2845-2855
[2.]
T. Gumbo, G.L. Drusano, W. Liu, L. Ma, M.R. Deziel, M.F. Drusano, et al.
Anidulafungin pharmacokinetics and microbial response in neutropenic mice with disseminated candidiasis.
Antimicrob Agents Chemother, 50 (2006), pp. 3695-3700
[3.]
G.M. Gauthier, T.M. Nork, R. Prince, D. Andes.
Subtherapeutic ocular penetration of caspofungin and associated treatment failure in Candida albicans endophthalmitis.
Clin Infect Dis, 41 (2005), pp. e27-e28
[4.]
J.A. Dowell, W. Knebel, T. Ludden, M. Stogniew, D. Krause, T. Henkel.
Population pharmacokinetic analysis of anidulafungin, an echinocandin antifungal.
J Clin Pharmacol, 44 (2004), pp. 590-598
[5.]
J.A. Stone, X. Xu, G.A. Winchell, P.J. Deutsch, P.G. Pearson, E.M. Migoya, et al.
Disposition of caspofungin: role of distribution in determining pharmacokinetics in plasma.
Antimicrob Agents Chemother, 48 (2004), pp. 815-823
[6.]
J.A. Vazquez.
Anidulafungin: a new echinocandin with a novel profile.
Clin Therapeutics, 27 (2005), pp. 657-673
[7.]
J.A. Stone, S.D. Holland, P.J. Wickersham, A. Sterrett, M. Schwartz, C. Bonfiglio, et al.
Single- and multiple-dose pharmacokinetics of caspofungin in healthy men.
Antimicrob Agents Chemother, 46 (2002), pp. 739-745
[8.]
S.K. Balani, X. Xu, B.H. Arison, M.V. Silva, A. Gries, F. DeLuna, et al.
Metabolites of caspofungin acetate, a potent antifungal agent, in human plasma and urine.
Drug Metab Dispos, 28 (2000), pp. 1274
[9.]
M. Stogniew, F. Pu, T. Henkel, J. Dowell.
Anidulafungin biotransformation in human is by degradation not metabolism.
13th European Congress Clinical Microbiology and Infectious, pp. P1223
[10.]
P. Sandhu, W. Lee, X. Xu, B.F. Leake, M. Yamazaki, J.A. Stone, et al.
Hepatic uptake of the novel antifungal agent caspofungin.
Drug Metab Dispos, 33 (2005), pp. 676-682
[11.]
J.A. Dowell, M. Stogniew, D. Krause, B. Damle.
Anidulafungin does not require dosage adjustment in subjects with varying degrees of hepatic or renal impairment.
J Clin Pharmacol, 47 (2007), pp. 461-470
[12.]
J.A. Stone, S. Holland, S. LI, P. Wickersham, P. Deutsch, G. Winchell, et al.
Effect of hepatic insufficiency on the pharmacokinetics of Caspofungin.
41th Interscience Conference on Antimicrobial Agents and Chemotherapy, pp. A14
[13.]
D. Thye, T. Kilfoil, R. White, K.C. Lasseter.
Anidulafungin phamacokinetics in subjets with mild and moderate hepatic impairment.
41th Interscience Conference on antimicrobial agents and chemotherapy, pp. A34
[14.]
D. Thye, T. Kilfoil, Kifoil., T. Henkel.
Anidulafungin phamacokinetics in subjets with severe hepatic impairment.
42th Interscience Conference on antimicrobial agents and chemotherapy, pp. A1392
[15.]
J.A. Stone, C. Ballow, S.D. Holland, P.J. Deusch, W. Hauck, E. Pequignot, et al.
Single dose caspofungin pharmacokinetics in healthy elderly subjets.
40th Interscience Conference on antimicrobial agents and chemotherapy Washington, pp. 853
[16.]
T.J. Walsh, P.C. Adamson, N.L. Seibel, P.M. Flynn, M.N. Neely, C. Schwartz, et al.
Pharmacokinetics, safety, and tolerability of caspofungin in children and adolescents.
Antimicrob Agents Chemother, 49 (2005), pp. 4536-4545
[17.]
D.K. Benjamin Jr., T. Driscoll, N.L. Seibel, C.E. Gonzalez, M.M. Roden, R. Kilaru, et al.
Safety and pharmacokinetics of intravenous anidulafungin in children with neutropenia at high risk for invasive fungal infections.
Antimicrob Agents Chemother, 50 (2006), pp. 632-638
[18.]
T.H. Nguyen, T. Hoppe-Tichy, H.K. Geiss, A.C. Rastall, S. Swoboda, J. Schmidt, et al.
Factors influencing caspofungin plasma concentrations in patients of a surgical intensive care unit.
J Antimicrob Chemother, 60 (2007), pp. 100-106
[20.]
U. Frank, M. Greiner, I. Engels, F.D. Daschner.
Effects of caspofungin (MK-0991) and anidulafungin (LY303366) on phagocytosis, oxidative burst and killing of Candida albicans by human phagocytes.
Eur J Clin Microbiol Infect Dis, 23 (2004), pp. 729-731
[21.]
R. Petraitiene, V. Petraitis, A.H. Groll, M. Candelario, T. Sein, A. Bell, et al.
Antifungal activity of LY303366, a novel echinocandin B, in experimental disseminated candidiasis in rabbits.
Antimicrob Agents Chemother, 43 (1999), pp. 2148-2155
[22.]
T. Gumbo.
Impact of pharmacodynamics and pharmacokinetics on echinocandin dosing strategies.
Curr Opin Infect Dis, 20 (2007), pp. 587-591
[23.]
U. Theuretzbacher.
Pharmacokinetics/pharmacodynamics of echinocandins.
Eur J Clin Microbiol Infect Dis, 23 (2004), pp. 805-812
[24.]
D. Andes, D.J. Diekema, M.A. Pfaller, R.A. Prince, K. Marchillo, J. Ashbeck, et al.
In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model.
Antimicrob Agents Chemother, 52 (2008), pp. 539-550
[25.]
A. Louie, M. Deziel, W. Liu, M.F. Drusano, T. Gumbo, G.L. Drusano.
Pharmacodynamics of caspofungin in a murine model of systemic candidiasis: importance of persistence of caspofungin in tissues to understanding drug activity.
Antimicrob Agents Chemother, 49 (2005), pp. 5058-5068
[26.]
M.A. Pfaller, D.J. Diekema, L. Boyken, S.A. Messer, S. Tendolkar, R.J. Hollis, et al.
Effectiveness of anidulafungin in eradicating Candida species in invasive candidiasis.
Antimicrob Agents Chemother, 49 (2005), pp. 4795-4797
[27.]
J.C. Bowman, P.S. Hicks, M.B. Kurtz, H. Rosen, D.M. Schmatz, P.A. Liberator, et al.
The antifungal echinocandin caspofungin acetate kills growing cells of Aspergillus fumigatus in vitro.
Antimicrob Agents Chemother, 46 (2002), pp. 3001-3012
[28.]
R. Petraitiene, V. Petraitis, A.H. Groll, T. Sein, R.L. Schaufele, A. Francesconi, et al.
Antifungal efficacy of caspofungin (MK-0991) in experimental pulmonary aspergillosis in persistently neutropenic rabbits: pharmacokinetics, drug disposition, and relationship to galactomannan antigenemia.
Antimicrob Agents Chemother, 46 (2002), pp. 12-23
[29.]
N.P. Wiederhold, D.P. Kontoyiannis, J. Chi, R.A. Prince, V.H. Tam, R.E. Lewis.
Pharmacodynamics of caspofungin in a murine model of invasive pulmonary aspergillosis: evidence of concentration-dependent activity.
J Infect Dis, 190 (2004), pp. 1464-1471
[30.]
Ostrosky-Zeichner L, Rex JH, Pappas PG, Hamill RJ, Larsen RA, Horowitz HW, et al. Antifungal susceptibility survey of 2,000 bloodstream Candida isolates in the United States. Antimicrob Agents Chemother. 200;47:3149-54.
[31.]
D.A. Stevens, M. Espiritu, R. Parmar.
Paradoxical effect of caspofungin: reduced activity against Candida albicans at high drug concentrations.
Antimicrob Agents Chemother, 48 (2004), pp. 3407-3411
[32.]
E.J. Ernst, M.E. Klepser, M.A. Pfaller.
Postantifungal effects of echinocandin, azole, and polyene antifungal agents against Candida albicans and Cryptococcus neoformans.
Antimicrob Agents Chemother, 44 (2000), pp. 1108-1111
[33.]
E.K. Manavathu, M.S. Ramesh, I. Baskaran, L.T. Ganesan, P.H. Chandrasekar.
A comparative study of the post-antifungal effect (PAFE) of amphotericin B, triazoles and echinocandins on Aspergillus fumigatus and Candida albicans.
J Antimicrob Chemother, 53 (2004), pp. 386-389
[34.]
Merck and co. Cancidas (caspofungin acetate for intravenous injection). Prescribing information (February 2005).
[35.]
Astellas Pharma. Mycamine (micafungin sodium for injection). Prescribing information (June 2006).
[36.]
Pfizer Inc. Eraxis (anidulafungin for injection). Prescribing information (March 2006).
[37.]
J.A. Stone, E.M. Migoya, L. Hickey, G.A. Winchell, P. Deutsch, K. Ghosh, et al.
Potential for interactions between caspofungin and nelfinavir or rifampin.
Antimicrob Agents Chemother, 48 (2004), pp. 4306-4314
[38.]
M.F. Hebert, D.K. Blough, R.W. Townsend, M. Allison, D. Buell, J. Keims, et al.
Concomitant tacrolimus and micafungin pharmacokinetics in healthy volunters.
J Clin Pharmacol, 45 (2005), pp. 1018-1024
[39.]
M.F. Hebert, R.W. Townsend, S. Austin, G. Balan, D.K. Blough, D. Buell, et al.
Concomitant ciclosporin and micafungin pharmacokinetics in healthy volunters.
J Clin Pharmacol, 45 (2005), pp. 954-960
[40.]
J.A. Dowell, M. Stogniew, D. Krause, T. Henkel, I.E. Weston.
Assessment of the safety and pharmacokinetics of anidulafungin when administered with cyclosporine.
J Clin Pharmacol, 45 (2005), pp. 227-233
[41.]
M. Stogniew, J. Dowell, D. Krause, T.J. Henkel.
Population pharmacokinetics confirms absence of anidulafungin drug-drug interactions.
14th European Congress of Clinical Microbiology and Infectious Diseases,
[42.]
J.A. Dowell, J. Scharanz, M. Stogniew, D. Krause, T. Henkel.
Assessment of the pharmacokinetics of anidulafungin in patients with invasive aspergillosis receiving concomitant liposomal amphotericin. European Congress of Clinical Microbiology and Infectious Disease.
Prague, (2004),
[43.]
P.L. Mc Cormack, C.M. Perry.
Caspofungin: a review of its use in the treatment of fungal infections.
Drugs, 65 (2005), pp. 2049-2068
[44.]
J. Dowell, J. Schranz, J. Wilson, A. Baruch, G. Foster.
Anidulafungina (ANID) pharmacokinetics are not affected by concomitant voriconazole (VORI).
14th European Congress of Clinical Microbiology and Infectious Diseases,
[45.]
J.A. Dowell, J. Schranz, A. Baruch, G. Foster.
Safety and pharmacokinetics of coadministered voriconazol and anidulafungin.
J Clin Pharmacol, 45 (2005), pp. 1373-1382
[46.]
A. Philip, Z. Odabasi, J. Rodriguez, V.L. Paetznick, E. Chen, J.H. Rex, et al.
In vitro synergy testing of anidulafungin with itraconazole, voriconazole, and amphotericin B against Aspergillus spp. and Fusarium spp.
Antimicrob Agents Chemother, 49 (2005), pp. 3572-3574
[47.]
J. Schranz, J. Dowell, D. Krause, T. Henkel.
Anidulafungin and cyclosporine: safe coadministration without dosing adjustment.
15th Congress of the International Society for Human and Animal Mycology,
[48.]
J.A. Dowell, M. Stogniew, D. Krause, T. Henkel, B. Damle.
Lack of pharmacokinetic interaction between anidulafungin and tacrolimus.
J Clin Pharmacol, 47 (2007), pp. 305-314
[49.]
R. Herbrecht, D. Graham, M. Schuster, T. Henkel, D. Krause, J. Scharanz, et al.
Safety and tolerability of combination anidulafungin (ANID) and liposomal amphotericin B (LAmB) for the treatment of invasive aspergillosis (IA).
Program and abstracts of Tandem Bone Marrow Trasplantation Meeting (Orlando, FI) Arlington Heights, IL, American Society for Blood and Marrow Transplantation, 91,
[50.]
R. Hurren, S.L. Davis, J.A. Vazquez.
What is the risk of disulfiram-like reaction during anidulafungin and metronidazole administration?.
47th ICAAC. Chicago,
[51.]
D.S. Krause, A.E. Simjee, C. Van Rensburg.
A randomized, double-blind trial of anidulafungin versus fluconazol for the treatment of esophageal candidiasis.
Clin Infect Dis, 39 (2004), pp. 770-775
[52.]
J. Schranz, D. Krause, T. Henkel.
Lack of infusion related adverse events with anidulafungin.
15th Congress of the International Society for Human and Animal Mycology,
[53.]
D. Thye, B. Shepherd, R.J. White, I.E. Weston, T. Henkel.
Anidulafungin: a Phase 1 Study to Identify the Maximum Tolerated Dose in Healthy Volunteers.
41th Interscience Conference on Antimicrobial Agents and Chemotherapy,
[54.]
D.S. Krause, J. Reinhardt, J.A. Vazquez, A. Reboli, B.P. Goldstein, M. Wible, Anidulafungin Invasive Candidiasis Study Group, et al.
Phase 2, randomized, dose-ranging study evaluating the safety and efficacy of anidulafungin in invasive candidiasis and candidemia.
Antimicrob Agents Chemother, 48 (2004), pp. 2021-2024
[55.]
D. Krause, J. Schranz, W. Birmingham.
Safety results from a Phase 3, randomized, double-blind, double-dummy study of anidulafungin (ANID) vs fluconazol (FLU) in patients with esophageal candidiasis (EC).
41th Interscience Conference on Antimicrobial Agents and Chemotherapy,
[56.]
J.A. Schranz, D. Krause, B.P. Golstein, T. Henkel.
Efficacy of anidulafungin (ANID) for the treatment of candidemia.
43th Interscience Conference on Antimicrobial Agents and Chemotherapy,
[57.]
K.A. Marr, R. Hachem, G. Papanicolaou, J. Somani, J.M. Arduino, C.J. Lipka, et al.
Retrospective study of the hepatic safety profile of patients concomitantly treated with caspofungin and cyclosporine A.
Transpl Infect Dis, 6 (2004), pp. 110-116
Copyright © 2008. Elsevier España S.L.. Todos los derechos reservados
